fulspot.blogg.se

Salaries, reviews, and more – all posted by employees working at … See what employees say it’s like to work at Silverback Therapeutics. Working at Silverback Therapeutics – Glassdoor Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce

Silverback Therapeutics Axes Lead Immuno-Oncology … Silverback Therapeutics is halting its clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring … Silverback Halts Oncology Programs, Lays Off 27% Of Staff Silverback Therapeutics became the latest biotech to undertake a “strategic realignment” Thursday, revealing it would drop its two lead … Silverback falls on hard times, axing lead I/O candidates and laying off more than a fourth of staff Silverback falls on hard times, axing lead I/O candidates and … With more than 30 layoffs tallied by Fierce Biotech, the overpopulated industry is being forced to cut down. Layoff surge hits 3 more biotech companies Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its … Recent News and Discussions About Silverback Therapeutics Layoffs Silverback Therapeutics shuts down oncology program, plans … The Seattle-based company is shuttering its oncology programs after reporting poor clinical results for its lead compound for solid tumors. Prior results do not guarantee similar outcomes.On Thursday, Silverback Therapeutics announced plans to lay off 27% of its workforce. For more information about the firm, please visit Attorney advertising. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

is a nationally recognized law firm with offices in New York, California, and South Carolina. There is no cost or obligation to you.īragar Eagel & Squire, P.C. If you purchased or otherwise acquired Silverback shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at telephone at (212) 355-4648, or by filling out this contact form. Investors have until Januto apply to the Court to be appointed as lead plaintiff in the lawsuit.Īccording to the filed complaint, (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. (“Silverback” or the “Company”) (NASDAQ: SBTX) in the United States District Court for the Western District of Washington on behalf of all persons and entities who purchased or otherwise acquired Silverback securities between Decemand September 10, 2021, both dates inclusive (the “Class Period”) and/or pursuant to the DecemIPO. 04, 2021 (GLOBE NEWSWIRE) - Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Silverback Therapeutics, Inc.